Bacillus anthracis elaborates a poly-γ-D-
Spores of Bacillus anthracis are the causative agents of anthrax disease (1) . Upon entry into their hosts, spores germinate and replicate as vegetative bacilli (1) . The formation of a thick capsule encasing vegetative forms enables bacilli to escape granulocyte and macrophage mediated phagocytosis, and the pathogen eventually disseminates throughout all tissues of an infected host (2, 3) . Bacilli secrete lethal and edema toxins, which cause macrophage necrosis and precipitate anthrax death (4) (5) (6) (7) . The genes providing for toxin and capsule formation are carried on two large virulence plasmids, pXO1 and pXO2, respectively (8, 9) . Loss of any one plasmid leads to virulence attenuation, a feature that has been exploited for the generation of vaccine-type strains (10) (11) (12) (13) (14) .
Unlike polysaccharide-based capsules that are commonly found in bacterial pathogens, the capsular material of B. anthracis is composed of poly-D-γ-glutamic acid (PDGA) (3) . All the genes necessary for capsule biogenesis are located in the capBCADE gene cluster on plasmid pXO2 (15) (16) (17) (18) (19) . CapD is the only protein of this cluster that is located on the bacterial surface (16) . CapD shares sequence similarity with bacterial and mammalian γ-glutamyl transpeptidases (GGT; EC 2.3.2.2) (17) . GGTs belong to the N-terminal nucleophile hydrolases (Ntn) family (CATH id 3.60.60.10) (20) . These enzymes assemble as a single polypeptide chain, and acquire activity by undergoing autocatalytic processing to heterodimer.
Bacterial GGTs catalyze the first step in glutathione degradation. For example, Helicobacter pylori GGT removes glutamate from glutathione tripeptide via the formation of a γ-glutamyl acyl enzyme. This intermediate is resolved by the nucleophilic attack of a water molecule, causing the release of γ-glutamate (21, 22) . Mammalian enzymes transfer the γ-glutamyl intermediate to the amino group of a peptide, thereby completing a transpeptidation reaction (23). The B. anthracis CapD precursor is also programmed for autocatalytic cleavage (17) . Similar to mammalian GGTs, CapD also catalyzes a transpeptidation reaction, however this reaction promotes the covalent linkage of PDGA to the bacterial envelope (16, 24) . We have recently demonstrated the cell wall anchor structure of capsule filaments in the envelope of B. anthracis, identifying an amide bond between the terminal carboxylgroup of PDGA and the side amino group of m-diaminopimelic acid crossbridges within muropeptides (24) . The CapD catalyzed transpeptidation reaction could be recapitulated in vitro using purified recombinant CapD, γ-D-Glu n peptide and muropeptide substrates (24) . In the absence of the physiological nucleophile (muropeptides), CapD acyl intermediates can be resolved by the nucleophilic attack of water to generate hydrolysis products.
Here we report the high-resolution crystal structure of CapD in the absence and presence of a glutamate dipeptide and compared it to the known structures of H. pylori and Escherichia coli GGTs. By combining structural, genetic and biochemical approaches, we identify the unique features of CapD that distinguish the protein from GGTs and detect several residues that are important for CapD autocatalytic cleavage and PDGA processing. This structural information will further the development of small molecule inhibitors that disrupt CapD activity and that may be useful as anti-infective therapies for anthrax.
EXPERIMENTAL PROCEDURES
Bacterial strains and growth conditions -B. anthracis Ames and E. coli were grown in Luria Bertani growth medium for DNA isolation and protein purification, respectively. For PDGA production, B. anthracis was grown on NBY agar supplemented with 0.8% sodium bicarbonate and 10% heat inactivated horse serum (Gibco) at 37˚C in 5% CO 2 as described (24) . Reagents were purchased from Sigma, unless otherwise noted.
DNA manipulations -DNA from B. anthracis Ames was isolated using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI). The DNA sequence of plasmid pXO2 (GenBank accession NC_007323) was used to design primers to amplify the CapD open reading frame by polymerase chain reaction (PCR) with the following primer pair 5' TACTTCCAATCCAATGCGTTCAACAA AATAAAAGACAGT and 5' TTATCCACTTCCAATGTCATTTATTTG ATTTCCAAGTTCC.
The amplified product was directly cloned in the ligation independent cloning vector pMCSG19 (25) . This primer design avoids cloning of the putative signal peptide of 28 residues (predicted by the SignalP 3.0 server www.cbs.dtu.dk/services/SignalP/). pMCSG19 vector encodes the maltose binding protein (MBP) sequence followed in order by: (i) TVMV protease cleavage site, (ii) hexa-histine tag (His 6 -tag), (iii) TEV protease cleavage site and (iv) target protein.
Upon cleavage with TEV protease, three residues (SerAsnAla) are added at the Nterminus of the target protein.
For site directed mutagenesis, the QuickChange Site Directed strategy from Stratagene was employed. The pMCSG19-capD plasmid was used as a template for amplification of DNA with pairs of primers that introducing a discrete change of either (26) (Scientific Reagents, Inc.). Cells were grown in the presence of ampicillin and kanamycin 100 and 30 μg/ml, respectively to an optical density at 600 nm of 0.6 and isopropyl-α-Dthiogalactoside (IPTG, 1 mM) was added to induce the expression of the fusion protein.
MBP was removed in situ upon production of the TVMV protease encoded on plasmid pRK1037. 4 h after addition of IPTG, cells were harvested, suspended in 5 volumes of lysis buffer (HEPES-KOH 50 mM pH 8.0, 500 mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, and 5% v/v glycerol), and stored at -20°C. Cells were thawed and lysed by sonication after the addition of protease inhibitors (Sigma, P8849) and lysozyme (1 mg/ml). Cell lysates were cleared by centrifugation at 30,000 g (RC5C-Plus centrifuge, Sorval) for 20 min, and filtered through 0.45 mm and 0.22 mm in-line filters (Gelman). His 6 -CapD was purified by immobilized metal affinity chromatography (IMAC-I) using a 5-ml HiTrap Chelating HP column charged with Ni +2 ions and buffer-exchange chromatography on a HiPrep 26/10 desalting column and AKTA TM Xpress (General Electric Health Systems). The His 6 -tag was cleaved using recombinant His 6 -TEV protease expressed from vector pRK508 (27) (a gift from Dr. D. Waugh, NCI). The protease over target protein ratio was 1:30 and incubation was performed at 4°C for 72 h after which the protease was removed using a 3 ml Ni-NTA chelating column (Qiagen).
The CapD protein was concentrated using a Centricon Plus-20 Centrifugal Concentrator (Millipore). The buffer was exchanged during this procedure to crystallization Buffer E (HEPES-KOH 20 mM pH 8.0, 250 mM NaCl, 2 mM dithiothreitol).
The selenomethionine (SeMet) derivative of CapD was prepared as described (28) . Briefly E. coli BL21 (DE3) cells producing MBP-His 6 -CapD were grown at 37°C in enriched M9 medium (25) supplemented with 0.4% glucose, 8.5 mM NaCl, 0.1 mM CaCl2, 2 mM MgSO4, and 1% thiamine. After the OD600 reached 1.2, 0.01% (w/v) each of leucine, isoleusine, lysine, phenylalanine, threonine, and valine were added to inhibit the metabolic pathway of methionine and promote SeMet incorporation. 60 mg of SeMet was added to one liter of culture and 15 min later protein expression was induced by addition of IPTG 1mM. Cells were incubated at 20°C overnight, harvested, suspended in lysis Buffer D (500mM NaCL, 50 mM HEPESNa pH 8.0, 10 mM imidazole, 10 mM β-mercaptoethanol, and 5% v/v glycerol, 50 mg protease inhibitor cocktail) and stored at -80ºC. The SeMet derivative was purified as described earlier.
Amino acid composition analysisEdman degradation was used to identify the N-terminal sequence of small chains of CapD and mutant variants. The analysis was performed on a Beckman 7300 Analyzer at the W. M. Keck Foundation Biotechnology Resource Laboratory, Yale University.
Enzyme assay -CapD activity was assayed using γ-D-polyglutamic acid (PDGA) from B. anthracis as the substrate. PDGA was isolated as described (24) . PDGA degradation by CapD wild type and mutants was performed following a modified protocol (16) . PDGA (100 µg) was incubated with 2 µM of enzyme in a 20 µL reaction volume and HEPES-KOH buffer 20 mM, pH 7.5. Reactions were incubated at 37ºC for 2 h and products separated on 2.5% agarose gel. PDGA in the gel was visualized with methylene blue stain (Molecular Research Center, Inc. Cincinnati, OH).
For hydrolysis of the FRET substrate, 400 pmol γ-D-glutamic acid pentamer (Abz-[γ-D-Glu] 5 -Dpn) were added to a final volume reaction of 40 µL containing 20 pmol of enzyme. The assay was performed in HEPES-KOH buffer 25 mM containing 1% Tween-20 at pH 7.5 and 21ºC. Increase in fluorescence was measured in a FluoroMax-2 (Horiba Jobin Yvon Inc., Edison, NJ).
Protein crystallization -CapD crystallization conditions were established with the help of the Mosquito robot (TTP Labtech) using the sitting drop vapor diffusion technique in a 96-well CrystalQuick plate (Greiner). Crystallization screens included Index, Crystal Screen (Hampton Research), Wizard (Emerald Biosystems), and SM4 and SM5 (Nextal). For structure determination the complete data set was collected from orthorhombic crystals grown in a crystallization solution containing PEG3350 12.5%, 0.1 M LiSO 4 and 0.1 M Na-HEPES 7.0. Prior to data collection, the concentration of the PEG3350 in the crystallization solution was increased to 32% for cryoprotection and the crystals were flash cryo-cooled in liquid nitrogen. Three segments of a single, long crystal were used to collect complete data set for structure determination. In course of crystal optimization the monoclinic crystal form was obtained from PEG3350 15%, PEG400 8%, 0.05 M LiSO4 and 0.1 M Na-HEPES pH 7.0. These crystals diffract to high resolution of 1.80 Å. Prior to data collection these crystals were cryoprotected using 15% glycerol and crystals were flash cryo-cooled in liquid nitrogen.
X-ray diffraction data collectionDiffraction data were collected at 100 K at the 19ID beamline of the Structural Biology Center at the Advanced Photon Source at Argonne National Laboratory using the program SBCcollect. For phasing a singlewavelength anomalous diffraction (SAD) data set was collected to 2.30 Å resolution at the wavelength near the selenium absorption peak (λ=0.9794 Å) from one SeMet labeled protein crystal (space group P2 1 2 1 2 1, unit cell dimensions a = 47.70, b = 72.00, c = 128.85 Å). The high-resolution data (1.80 Å) were collected from monoclinic crystal (space group P2 1, unit cell dimensions a = 52.67, b = 120.62, c = 77.38 Å, β = 90.87º). All data was processed and scaled with HKL3000 suite (Tables 1 and 2 
) (29).
Structure determination and refinementThe CapD crystal structure was first determined using SAD phasing and data obtained from an orthorhombic crystal. Thirteen selenium sites were located using the program SHELEXD (30) . These selenium sites were used for phasing to 2.30 Å with the program MLPHARE (31). After density modification (DM) (32), a partial model of 369 residues without side chains was obtained from an automatic model building trial using the program RESOLVE (32). All the above referenced programs are integrated within the program suite HKL3000 (29) . Based on the initial partial model, most parts of the CapD monomer were built manually using COOT (33) . The electron density for most of the CapD was of high quality. After several cycles of manual model adjustment and improvement using COOT, the model was refined using REFMAC (34) ( Table 1) .
The highresolution structure was obtained using data collected from a monoclinic crystal. The structure was determined using CapD 2.30 Å structure as a starting model and MOLREP of CCP4 program suite (14) . The model was refined using REFMAC (34) ( Table 2) .
Modeling of the di--D-Glu substrateThe model of CapD with the physiological substrate di-γ-D-Glu was created using the Dundee PRODRG sever (davapc1.bioch.dundee.ac.uk/prodrg) and refined with monomer library sketcher. The normalized structure of di-γ-D-Glu was modeled into the omit electron density map and real space refinement to the maximum fitness of the ligand to the map. Two orientations of the ligand between enzyme and substrate were considered. Based on the geometry analysis and density fit analysis the best fit one was showed in Fig. 2C .
RESULTS

Structure Determination -Recombinant
CapD lacking the N-terminal signal peptide within the first 28 amino acids (residues 29-528) was produced in E. coli. The recombinant protein underwent autocatalytic processing to yield a stable heterodimer with large L and small S chains, residues 29-351 and 352-528, respectively. The N-terminal amino acid sequence of the small subunit was verified by Edman degradation. Orthorhombic and monoclinic crystals of the CapD heterodimer were obtained. The structure of CapD was determined by SAD phasing of the orthorhombic crystal form and SeMet labeled protein using HKL3000 (29) and refined to 2.30 Å (R = 19.7%, Rfree = 25.2%) ( Table 1 ). This crystal form contained one CapD molecule with bound L-Glu-L-Glu dipeptide (di-α-L-Glu), a nonhydrolysable analog of poly-γ-D-glutamic acid, in the asymmetric unit. The peptide was acquired by CapD during protein expression in E. coli. The structure of CapD in monoclinic crystal was determined by molecular replacement, using CapD as a starting model and refined to 1.80 Å (R = 19.7%, Rfree = 24.2%). This crystal form contained two CapD molecules in the asymmetric unit, one with bound di-α-L-Glu and one unliganded ( Table 2) . Electron densities in both crystals were of high quality and generally continuous. Nevertheless, electron densities for residues 29-45, 337-351, i.e. the first 17 and the last 15 residues of the L chain, and residue 528, the last residue of the S chain, were poorly defined and these residues could not be modeled into the structure. At 1.80 Å, the heterodimer has overall dimensions of 60 × 45 × 35 Å and the crystal structure confirmed the discontinuity of the peptide backbone between residues 351 and 352, liberating the N-terminus of the S chain at Thr 352 . The L and S chains are highly intertwined throughout the structure with a 9,192 Å 2 surface area buried between them.
Overall Structure -CapD contains two central β-sheets stacked with clusters of 8 and 10 α-helices above and below, respectively (Fig. 1A) . Together these secondary structures form a 6-layer sandwich (α/α/β/β/α/α), a variation of the 4-layer sandwich (α/β/β/α) found in the structure of Ntn hydrolases. In the central β-sheet sandwich, strands are arranged in an anti-parallel fashion and both L and S chains contribute strands to the nearly flat β-sheets. The N-terminal portion of the L chain sequence provides the entire domain folded below the β-sheet sandwich, which is composed of 10 helices arranged in two layers (Fig. 1A) . The upper helical domain with 8 helices is composed of elements that are derived from both the L and the S chain, whereas a 3-stranded mixed β-sheet is provided by the S chain (Fig. 1A) .
A large, solvent-accessible groove is located in the middle of the molecule between the lower and upper domains. Three areas of strongly positive electrostatic potential on the surface of CapD form a Yshape and converge within the deep cleft in the middle of the molecule (Fig. 1B) . The active site nucleophile, Thr 352 , is positioned at the bottom of this cleft. Comparison of the CapD structure with other protein structures deposited in the Protein Data Bank (PDB) was performed with the SSM server (35) and identified GGT of E. coli, H. pylori and Thermoplasma acidophilum (36, 37) (Fig. 1B) . These proteins display 30-33% overall sequence identity with CapD. An alignment of the primary sequences of CapD and GGT homologues is shown in Supplementary Fig. 1 . Similar to CapD, GGTs adopt the Ntn fold (Fig. 1C) , which enables members of this family of enzymes to engage in autocatalytic processing. The side chain of the newly liberated N-terminal residue within the S chain is thereby incorporated into a β-sheet where it can function as a nucleophile during catalysis.
Hence, autocatalytic processing is an absolute prerequisite for enzymatic activity, where the nucleophilic attack of an Nterminal cysteine, serine or threonine residue enables cleavage of scissile amide bonds and the formation of acyl intermediates (20, 36, 37) . CapD is most similar to GGTs where the catalytic residue is the first Thr of the newly processed S chains (Fig. 2) . This amino acid is Thr 352 in CapD and Thr 380 in H. pylori GGT.
Topology of ligands in the binding pocket -A well defined electron density was found in the active site of CapD and could be revealed as di-α-L-Glu (Fig. 1A , Fig. 2A and Supplementary Fig. 2 ). This compound represents a non-hydrolyzable analogue of γ-D-Glu n . Its presence in the active site is a serendipitous discovery. The γ-carboxylate group of the dipeptide forms a strong salt bridge with Arg 520 and maintains hydrogen bonds with the amide of Gly 429 and amine of Thr 352 . Thr 352 also forms a strong hydrogen bond with the α-carboxylate of glutamate (2.67 Å) (Fig. 2B) . In turn, the α-carboxylate of di-α-L-Glu engages additional hydrogen bonds with the amide of Gly 430 and through a water molecule with the amide of Asn 373 . Gly 429 -Gly 430 are located in a highly conserved sequence segment, GSPGG ( Supplementary Fig. 1) ; the corresponding glycine pair in E. coli and H. pylori GGTs has been shown to interact with the substrate, glutathione (36, 37) . Two residues are unique to CapD, Phe 374 and Arg 172 . The guanidine group interactions with the benzene ring (Fig. 2B ) may limit the access of water to the active site of CapD and could be responsible for the enzyme's catalytic attributes towards capsules anchoring rather than PDGA hydrolysis.
Based on the binding attributes of di-α-D-Glu, the physiological substrate, di-γ-DGlu peptide, was modeled into the active site of CapD by exploring two possible orientations. The best fit orientation between enzyme and substrate is shown in Fig. 2C Comparison of CapD structures with and without ligand -The CapD structure in monoclinic crystal contained one molecule with ligand and one without, suggesting conformational changes that can be associated with substrate binding (Fig. 3A) . Several α-helices in both the L and S chains were shifted toward the positively charged surface groove, resulting in a more compact appearance of the enzyme's complex with di-Glu. In addition, the loop region of Pro 494 -Phe 497 near the active site became more structured and formed a single turn helix (Fig. 3A) . Several side chains that contact the ligand and/or control access to the active site also showed significant conformational changes. Notably, Arg 520 assumes a different conformation in the absence of ligand (Fig. 3B) , which is also observed at low substrate occupancy in one of the crystal forms with ligand ( Fig. 2A) Fig. 1 ). Edman degradation of the small subunits of each purified variant revealed the sequence TTHFVIID, i.e. the expected N-terminal amino acid residues of the S chain. These results demonstrate further that none of the listed mutants abolished the autocatalytic properties of CapD. CapD cleavage of purified PDGA from B. anthracis was measured by separating reaction products by electrophoresis on a 2.5% agarose gel and staining capsular material with methylene blue. As CapD degradation products cannot be retained in the gel, the absence of capsule staining indicates enzyme cleavage of PDGA. With the exception of the Ser 372 Ala variant, all other CapD mutants displayed defects in their ability to cleave capsular material when compared to the wild-type enzyme (Fig.  4A) . These findings could be corroborated with a second assay, using a γ-D-glutamate pentamer with the fluorescenec quencher ortho-aminobenzoyl (Abz) at the N-terminus and the 2,4 dinitrophenyl (Dpn) fluorophore at the γ-carboxyl group (Abz-[γ-D-Glu] 5 -Dpn). A strong increase in fluorescence, indicating substrate cleavage, was observed upon incubation of substrate with wild-type CapD. Here again, the Ser 372 Ala variant retained most of the activity of wild-type CapD, whereas Thr 368 Ala, Thr 370 Ala, and Arg 520 Ala displayed no activity (Fig. 4B) . Thus, although Thr 368 , Thr 370 , and Arg 520 Ala are not required for autocatalytic processing of CapD, these residues proved to be essential for enzyme catalysis. Ser 372 , on the other hand, appears to be required for full cleavage activity of CapD, but is otherwise dispensable for catalysis. Thr 398 of H. pylori GGT, a residue that occupies the analogous position to Thr 370 of CapD, is also dispensable for autoprocessing but necessary for glutathione hydrolysis. Boanca and colleagues proposed that Thr 398 may assume the important function of orienting the catalytic residue, Thr 380 , and thereby enhance its reactivity (37) .
A similar function could apply to Thr 370 of CapD.
DISCUSSION
We report here for the first time the crystal structure of B. anthracis CapD, which shares with other GGT hydrolases the overall Ntn fold as well as conserved amino acid features of their active site. Nevertheless, the CapD structure also displays unique features that likely contribute to the enzyme's ability to perform a transpeptidation reaction that immobilizes PDGA capsular material in the bacterial cell wall envelope. We presume the Ntn fold and active site nucleophile at the N-terminus of the S chain account for the ability of these enzymes to undergo autocatalytic processing. In Ntn hydrolases, self cleavage involves the formation of an acyl-enzyme intermediate with key catalytic residues and properly positioned water molecule to resolve the intermediate. (36, 37) . For example, the crystal structure of a Thr 391 Ala variant of E. coli GGT, which cannot undergo autocatalytic processing, revealed that the P-segment of the precursor reaches over the active site (38) (Fig. 5) . In CapD, the bound substrate di-α-D-Glu assumes a similar position to the loop of GGTs; please note that in GGTs there is an insert of ten residues between residues 399-400 in CapD ( Supplementary Fig. 1 ) resulting in significantly longer loop that constrains access to the active site in GGTs. Even though its active site is widely open in CapD, this enzyme cannot hydrolyze glutathione and cannot be inhibited by known GGT inhibitors (24) . We presume that the remarkable, extended Y-shaped positive electrostatic potential on the surface of CapD contributes to substrate recognition that is polymeric in nature. In vivo, CapD transfers poly-γ-glutamate chains to the cell wall, a reaction that can be recapitulated in vitro by using muropeptides (transpepditation reaction) (24 Conformational changes in the active site of CapD upon ligand binding. The structure of CapD (carbon atoms in aqua) with bound di-α-L-Glu (carbon atoms in yellow) is compared with ligand free CapD structure (in orange). Key residues are labeled. Two conformations of Arg520 observed in the monoclinic crystal are labeled "c1" and "c2" for "ligand-bound" and "ligandfree" conformations, respectively. The values in parentheses of resolution, completeness, and I/ (I) correspond to the outermost resolution shell. 
